On ECHEMI
Home > Drugs > KBN-ZHEJIANG Pharmaceutical Co., Ltd.
KBN-ZHEJIANG Pharmaceutical Co., Ltd.
  • Founded in:

    1982-02-20
  • Country:

    China China
  • Address:

    No. 340, Yunhai Road, Jiaxing Economic Development Zone, Zhejiang Province
  • Tax NO.:

    913304011464602960
  • Registered Funds:

    36.5 million yuan
  • Website:

  • Email:

Related Drugs
Cefaclor Dispersible Tablets
The main ingredient is cefaclor: (6R,7R)-7-[(R)-2-amino-2-phenylacetylamino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
Name Description Content CAS NO. Registered Holders
Cefaclor

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

More

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

53994-73-3 29
Cefaclor Dispersible Tablets
The main ingredient is cefaclor: (6R,7R)-7-[(R)-2-amino-2-phenylacetylamino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
Name Description Content CAS NO. Registered Holders
Cefaclor

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

More

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

53994-73-3 29
Guacitriol dry suspension
The main ingredient is guacitsal.
Name Description Content CAS NO. Registered Holders
guacetisal

It has non-specific anti-inflammatory and antipyretic effects. This product is partially converted into guaiacol salicylate, guaiacol and salicylic acid in the gastrointestinal tract. Most of it is absorbed and distributed in the brain, muscle, fat, testis, plasma, heart, liver, spleen, lung and kidney in the form of salicylic acid and guaiacol salicylate. It is mainly excreted through the kidney in the form of salicylic acid, and the binding rate of guaiacol salicylate to plasma protein is 25.8%.

More

It has non-specific anti-inflammatory and antipyretic effects. This product is partially converted into guaiacol salicylate, guaiacol and salicylic acid in the gastrointestinal tract. Most of it is absorbed and distributed in the brain, muscle, fat, testis, plasma, heart, liver, spleen, lung and kidney in the form of salicylic acid and guaiacol salicylate. It is mainly excreted through the kidney in the form of salicylic acid, and the binding rate of guaiacol salicylate to plasma protein is 25.8%.

55482-89-8 2
Lysine Inositol Vitamin B12 Oral Solution
The lysine hydrochloride (C6H14N2O2?HCl) content of this product should be 90.0% to 110.0% of the labeled amount.
Name Description Content CAS NO. Registered Holders
L-Lysine hydrochloride

One of the essential amino acids for maintaining nitrogen balance in the body, it has the function of promoting human growth and development

More

One of the essential amino acids for maintaining nitrogen balance in the body, it has the function of promoting human growth and development

10098-89-2 16
Inositol

Can promote fat metabolism in the liver

More

Can promote fat metabolism in the liver

87-89-8 8
Vitamin B12

It is an important coenzyme for DNA synthesis in the body

More

It is an important coenzyme for DNA synthesis in the body

68-19-9 16
Dihydroartemisinin piperaquine tablets
Name Description Content CAS NO. Registered Holders
DHQHS 2

71939-50-9 3
Piperaquine

83764-65-2 1
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.